Lecrolyn Sine

Sodium cromoglicate, the active ingredient in Lecrolyn Sine, is a mast cell stabilizer presented as an ophthalmic solution for ocular use. It is employed to manage allergic conjunctivitis and mast cell‑mediated ocular allergy in patients requiring topical anti‑allergic therapy.

GNH USA supplies Lecrolyn Sine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lecrolyn Sine is a mast cell stabilizer used to treat ocular allergic conditions by preventing mediator release.

Allergic conjunctivitis: reduces itching, redness and watery discharge caused by allergens. Mast cell‑mediated ocular allergy: stabilises ocular mast cells to prevent inflammation. Seasonal allergic eye disease: provides relief during pollen seasons by limiting histamine release.

Adverse reactions are generally mild and localized to the eye.

Common Side Effects: - Transient ocular irritation or burning sensation. - Stinging upon instillation. - Blurred vision lasting a few minutes. - Mild conjunctival hyperemia. - Foreign body sensation. - Temporary increased tear production.

Serious or Rare Side Effects: - Allergic contact dermatitis of the eyelid. - Severe eye inflammation or keratitis. - Corneal ulceration. - Anaphylactic reaction (extremely rare).

When using Lecrolyn Sine, consider the following safety measures.

Avoid use with contact lenses: remove lenses before and after administration. Discontinue if severe irritation occurs: seek ophthalmic evaluation. Do not exceed prescribed frequency: follow prescriber instructions. Keep out of reach of children: store securely. Store at room temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Lecrolyn Sine may interact with other ophthalmic agents; monitor for combined effects.

Major Interactions (Avoid): - Topical ocular anesthetics: may increase ocular irritation. - Other mast cell stabilisers: concurrent use offers no added benefit and may increase local discomfort.

Moderate Interactions (Monitor Closely): - Antihistamine eye drops: may reduce the stabilising effect of sodium cromoglicate. - Systemic antihistamines: additive sedation is unlikely but monitor patient response. - Contact lens cleaning solutions: may affect drug stability; ensure lenses are removed during treatment.